Report Overview
The market for digital therapeutics was valued at US$ 3.06 billion in 2022 and is anticipated to increase to US$ 28.87 billion by 2030, expanding at a CAGR of 29.4% from 2023 to 2030.
Digital therapeutics are evidence-based treatments that include software, applications, and programmes for the diagnosis and treatment of physical, mental, and behavioural disorders. To enhance patient care and health outcomes, digital therapeutics may be employed alone or in combination with drugs, technology, or other therapies. Digital therapy uses a regulated intervention to target the clinical results in line with the established clinical indication and patient population. For unmet medical needs, digital therapies offer patients, providers, and payers new therapeutic options.
For More Insights request free Sample: https://www.datamintelligence.com/download-sample/digital-therapeutics-market
Market Dynamics
The demand for digital therapeutics is increasing due to their benefits, including their ability to change behaviour, be user-friendly, convenient for patients, and improve drug compliance, as well as new technological developments in digital therapeutics.
Market expansion is anticipated to be fueled by new technical developments and rising benefits of digital therapies.
Due to their benefits, such as their ability to change behaviour, be user-friendly, convenient for patients, and enhance drug compliance, digital therapies are in high demand. The use of healthcare applications to diagnose, treat, and manage illness is spreading along with the proliferation of smartphones and tablets. It allows for the simple recording and monitoring of patients' vital signs without the need for intervention. Mobile consultations are made possible, and chronic disease management is made effective. Digital medicines offer the chance to lengthen product life cycles, distinguish items in development, and close market gaps caused by traditional medication.
Technological advancements and the emergence of novel digital therapies will promote market expansion. For instance, Pear Therapeutics' Somerset, a prescription digital treatment for people with chronic insomnia, was approved by the Food and Drug Administration (FDA) in March 2020. Using a smartphone, tablet, or other comparable device, Somryst is a customised form of cognitive behavioural treatment for insomnia (CBTi) that is administered over the course of nine weeks. It can only be obtained with a prescription from a qualified healthcare provider and is only meant to treat the symptoms of people with chronic insomnia who are 22 years of age or older. Patients can receive Somryst as a digital treatment with ease and on a large scale.
It is anticipated that patient data privacy and an unstable payment model will impede industry expansion.
Numerous digital therapies that are still in the early stages of development are impeding the market. Concerns over patient data protection and shaky payment methods could harm the sector.
View Full Report: https://www.datamintelligence.com/research-report/digital-therapeutics-market
Digital Therapeutics Market Companies
Key players are 2Morrow Inc., Livongo Health, Inc., Medtronic Plc., Omada Health, Inc., Pear Therapeutics, Inc., Proteus Digital Health, Inc., Resmed, Inc. (Propeller Health), Voluntis, Inc., Welldoc, Inc.
Related Reports:
Sign in to leave a comment.